Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

BOTHELL, WA and VANCOUVER, May 14 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the release of two abstracts to be presented during oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts are now available to the public online on the OncoGenex Web site at www.oncogenex.com in addition to the ASCO Web site, www.abstract.asco.org.

Highlights from the OGX-011 Abstract

At the time data was submitted to ASCO and as previously disclosed in December 2008, the preliminary median overall survival in patients with advanced prostate cancer who were treated with OGX-011 plus docetaxel in a randomized Phase 2 trial was 27.5 months compared to 16.9 months for patients treated with docetaxel alone. The hazard ratio (HR), a measure used to determine the difference in survival between treatment groups, was 0.60, representing a 40% reduction in the rate of death for patients treated with OGX-011. New data disclosed today include a prospectively defined multivariate analysis evaluating variables predictive of overall survival. The analysis defined only three variables predictive of overall survival: performance status, presence of visceral metastasis and assignment to the OGX-011 treatment arm. Based on the multivariate analysis, patients treated with OGX-011 had a rate of death 46% lower than patients treated with docetaxel alone (HR=0.54; p=0.04).

The abstract represents survival data as of November 2008. Final survival data as of April 2009 for this trial will be presented during an oral presentation at ASCO.

Highlights from the OGX-427 Abstract

At the time the data was submitted to ASCO, 34 patients with a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... STONY BROOK, NY (PRWEB) July 30, 2014 ... (OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides ... Dr. Michael E. Hogan, Ph.D. Vice President of Life ... in mid-September. , Dr. Hogan will lead ... to form business relationships with biotech and healthcare customers, ...
(Date:7/30/2014)... Yuma Regional Cancer Center Officially ... brings comprehensive cancer care to Yuma, Arizona. , ... Center has officially opened. A Mayo Clinic Care ... such as open, semi-private and private infusion rooms, ... Resource Center, hematology, rehabilitation center, a pain management ...
(Date:7/30/2014)... COLLEGE PARK, Md. , July 30, 2014 ... with biological components to interrogate biology, but such ... control biology. As such, researchers ... cells for in vitro metabolic engineering ... metabolism on a chip. New devices are envisioned ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... 4 Lentigen Corporation, a biotechnology company specializing ... delivery technologies, and Expression Therapeutics, a biotechnology company ... collaborative agreement to co-develop novel cell and protein ... blood clotting disorder caused by a mutation in ...
... ) announced today that it will release its fourth quarter ... 24, 2009. The Company will host a telephone conference call ... Eastern Time. A question and answer session will follow. Conference ... conference call, interested parties in the United States and Canada ...
... ST. LOUIS, Feb. 4 On the heels of a ... MON ) executives will explain to investors this month where ... rest of this year and how it plans to achieve ... profit level by fiscal 2012. Terry Crews, chief financial officer, ...
Cached Biology Technology:Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February 2
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
(Date:7/30/2014)... JOSE, Calif. , July 30, 2014 /PRNewswire/ ... partnership with the United States Air Force Research ... proposed by Binghamton University ... human performance monitoring (HPM). The $425,000 project, with ... electronics packaging firm i3 Electronics, Inc. ( ...
(Date:7/29/2014)... USA The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics. , ... BRAIN Initiative in the United States, and a special ... and provide examples of the impact that optics and ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... and Avalon Technology partner on new ... aviation-related ... Inc.,(OTC Bulletin Board: CTHH) ( http://www.catcherinc.com ), a leader ... Technology ( http://www.avalontechnology.com ), a leading,integrator of managed mobile ...
... resulting from higher CO2 could boost the amount ... new study looks at a poorly understood process ... Sayer, postdoctoral fellow at the Smithsonian Tropical Research ... University of Minnesotas Department of Ecology, Evolution and ...
... Boulder, CO, USA Two hundred years ago Lewis and ... deal of scientific research with its descriptions of territory acquired ... be disappointed by the absence of living megafauna, the area ... volume published by the Geological Society of America makes clear ...
Cached Biology News:CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4Complex carbon picture clearer 2
... The LTQ XL extends the legendary ... techniques to generate structural information through Thermo ... Thermo Scientific's LTQ XL is the only ... PQD, ETD and CID. Pulsed Q ...
... Varian, Inc.'s CP-4900 is a ... always delivers the information you ... When the composition of gas ... generation micro-Gas Chromatograph generates more ...
... The PolarScreen Peroxisome Proliferator-Activated Receptor-gamma ... a sensitive and efficient method ... PPARGamma ligands using fluorescence polarization ... PPARGamma-Ligand binding domain (PPARGamma-LBD) with ...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: